Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Recent News

  • Therma Bright and Orpheus Provide Development Update for its COVID-19 Rapid Saliva Test, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - September 15, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to provide an update on the development progress of the CoviSafeTM rapid test for detecting SARS-CoV-2 in saliva. As announced on September 3, 2020, Orpheus identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19. These polypeptides, and...

    2020-09-15 5:00 AM ET
  • Therma Bright und Orpheus identifizieren neue biologische Nachweismoleküle für den COVID-19-Schnelltest

    Toronto, Ontario--(Newsfile Corp. - Freitag, 4. September 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Technologieunternehmen für medizinische Geräte, freut sich bekannt zu geben, dass sein Entwicklungspartner Orpheus Medica Inc. ("Orpheus") eine Reihe von Polypeptiden für das Screening und den Nachweis des COVID-19 verursachenden Virus (SARS-CoV-2) identifiziert hat. Die von Orpheus und seinen akademischen Mitarbeitern durchgeführten Forschungsarbeiten haben zu mehreren hochwertigen Polypeptiden geführt, die das COVID-19-Virus erkennen und deutlich von anderen Coronavirus-Typen wie SARS oder...

    2020-09-04 9:18 AM ET
  • Therma Bright and Orpheus Identify Novel Biological Detection Molecules for COVID-19 Rapid Test

    Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that its co-development partner, Orpheus Medica Inc. ("Orpheus") has identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.The research carried out by Orpheus and its academic collaborators has resulted in several high-quality polypeptides that recognize the COVID-19 virus with clear distinction from other coronavirus types such...

    2020-09-03 8:58 AM ET
  • Therma Bright Provides Corporate Update

    Toronto, Ontario--(Newsfile Corp. - September 1, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides updates on the following:Further Testing of TherOZap® Technology Against the Dengue Virus; Redesign of InterceptCS™ Cold Sore Technology;Relaunch of BenePod® and Venowave® products;Joint development with Orpheus - CoviSafe™.Therma Bright Plans Further Testing of TherOZap® Technology Against the Dengue VirusAs previously outlined in its press releases on January 8, 2018 and September 4, 2019, the TherOZap® technology...

    2020-09-01 9:25 AM ET
  • Therma Bright schließt eine Vereinbarung mit Orpheus zur gemeinsamen Entwicklung des COVID-19 Speichel-Schnelltests von Orpheus Medica, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - Freitag, 28. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, eine endgültige Vereinbarung zur gemeinsamen Entwicklung mit Orpheus Medica Inc. ("Orpheus") oder (Therma & Orpheus, die "Parteien") unterzeichnet zu haben. Diese Vereinbarung eröffnet Therma Zugang zu der neuen biologischen Plattform von Orpheus und ermöglicht die gemeinsame Entwicklung eines Speichel-Schnelltests zum Screening und Nachweis des Virus (SARS-CoV-2), das COVID-19 verursacht. Im Rahmen dieser Vereinbarung wird...

    2020-08-28 9:01 AM ET
  • Therma Bright Enters into Co-Development Agreement with Orpheus Medica's COVID-19 Rapid Saliva Test, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus (SARS-CoV-2) causing COVID-19. Under this agreement,...

    2020-08-27 9:07 AM ET
  • Therma Bright Acquires Benepod(R) Pain Relief Technology and Other Innovative Medical Device Technology from Saringer Life Science Technologies Inc.

    Toronto, Ontario--(Newsfile Corp. - August 26, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has closed the transaction to acquire Benepod® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction for $425,000. The transaction includes the acquisition of...

    2020-08-26 5:00 AM ET
  • Update von Therma Bright zu den Transaktionen Saringer und Orpheus

    Toronto, Ontario--(Newsfile Corp. - Donnerstag, 20. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizingeräteunternehmen, gibt hiermit ein Update in Erwiderung auf Anfragen von Aktionären. Saringer - Akquise von Vermögenswerten (Benepod®-Schmerzlinderungstechnologie)Wie bereits zuvor angekündigt (siehe Pressemitteilungen vom 15. Januar, 8. April und 9. Juli 2020), hat Therma eine zufriedenstellende Due Diligence-Prüfung abgeschlossen und beabsichtigt, die Benepod®-Schmerzlinderungstechnologie und andere damit verbundene medizinische Gerätetechnologien sowie geistiges Eigentum von Saringer Life Science Technologies Inc. ("

    2020-08-20 4:17 PM ET